{"id":"W3186488369","doi":"10.1016/j.jtho.2021.07.008","title":"Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"Janssen Pharmaceuticals; Foundation Medicine; EMD Serono; Genentech; G1 Therapeutics; Puma Biotechnology; Bayer Fund; Mirati Therapeutics; Clovis Oncology; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; Pfizer; Incyte; F. Hoffmann-La Roche; AbbVie; Daiichi-Sankyo; Teva Pharmaceutical Industries; Roche; Novartis; Sanofi; Merck; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen","keywords":"Medicine; Alectinib; Internal medicine; Clinical endpoint; Oncology; Cohort; Asymptomatic; Confidence interval; Response Evaluation Criteria in Solid Tumors; Surrogate endpoint; Clinical trial; Phases of clinical research; Crizotinib; Lung cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000569655,0.000176555,0.0008612625,0.0001717172,0.00009156889,0.00001129107,0.00009969186,0.00009484978,0.00009733268],"category_scores_gemma":[0.0008698279,0.0001011449,0.0002897004,0.0004085778,0.000108227,0.0001391953,0.00003454675,0.0002838162,0.000001827961],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005274934,"about_ca_system_score_gemma":0.002184871,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006528822,"about_ca_topic_score_gemma":0.0003987219,"domain_scores_codex":[0.9977604,0.0005250513,0.0009752289,0.0002020692,0.0003126698,0.0002245855],"domain_scores_gemma":[0.9973814,0.0008792846,0.0009436428,0.0002211677,0.0004471641,0.0001273784],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4316121,0.0161704,0.002600176,0.00009632018,0.00722267,0.01406186,0.007522974,0.0005025195,0.003686658,0.00004296231,0.0005162249,0.5159651],"study_design_scores_gemma":[0.7463468,0.07396015,0.01730353,0.002443282,0.02623709,0.008856805,0.009116647,0.0002535576,0.08886544,0.0002081198,0.02596529,0.0004432439],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9858391,0.0007032095,0.0003951611,0.005448241,0.0009216933,0.001148909,0.0002035194,0.000007020571,0.005333182],"genre_scores_gemma":[0.9910618,0.0002200975,0.006864334,0.0002382324,0.0003226478,0.00004141883,0.00004400214,0.00001912765,0.001188323],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5155219,"threshold_uncertainty_score":0.4124568,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04395250547035683,"score_gpt":0.4840153234446429,"score_spread":0.440062817974286,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}